Ozempic and Fertility: What are the Risks?

Ozempic and Fertility: What Every Woman Needs to Know Before and During Treatment

Dr. Lucky Sekhon, a double board-certified reproductive endocrinologist and infertility specialist, addresses a topic that has become increasingly urgent as millions of women of reproductive age start GLP-1 medications. What does Ozempic do to fertility? Can you get pregnant on it? Should you stop it before trying to conceive? And what about the "Ozempic baby" trend that has been all over social media? Sekhon brings the clinical expertise to sort through the hype and the genuine concerns.

This video has particular relevance because the demographic most commonly starting GLP-1 medications for weight loss overlaps significantly with the demographic most likely to be thinking about fertility. Women in their late 20s through early 40s with obesity or PCOS (polycystic ovary syndrome) are prime candidates for both GLP-1 treatment and fertility planning. Understanding how these medications interact with reproductive health is not optional for this population.

The Ozempic Baby Phenomenon

Sekhon starts with the social media trend. Women have been reporting unexpected pregnancies after starting GLP-1 medications, even women who had been told they would have difficulty conceiving. The term "Ozempic babies" caught on, and the stories accumulated quickly enough to attract media attention and clinical interest.

Is there a real phenomenon here? Sekhon thinks yes, but the mechanism is not mysterious. Obesity impairs fertility through multiple pathways. It disrupts ovulation, alters hormone levels (particularly estrogen and androgens), creates insulin resistance that worsens PCOS, and can cause chronic low-grade inflammation in reproductive tissues. When women lose weight on GLP-1 medications, these pathways improve. Ovulation becomes more regular. Hormone levels normalize. Insulin sensitivity increases. Fertility improves.

For women with PCOS specifically, the insulin-sensitizing effects of GLP-1 medications may be particularly beneficial. PCOS is fundamentally a metabolic-reproductive disorder where insulin resistance drives excess androgen production, which suppresses ovulation. By improving insulin sensitivity and reducing androgens through weight loss, GLP-1 medications can restore ovulatory cycles in women who have not been ovulating regularly.

The practical upshot: if you are a woman of reproductive age on a GLP-1 medication and you are not actively trying to get pregnant, use contraception. Your fertility may be improving even if you do not realize it, and unintended pregnancies on medications that are not approved for use during pregnancy create difficult clinical situations.

The Safety Concern: GLP-1 Medications During Pregnancy

Sekhon is direct about this. GLP-1 medications are not approved for use during pregnancy, and the recommendation is to discontinue them before attempting conception. The standard guidance is to stop semaglutide at least two months before trying to conceive, based on the drug's half-life and the time needed for complete washout.

The reason for concern is not that human studies have shown birth defects or pregnancy complications from GLP-1 medications. There is not enough human data to draw those conclusions in either direction. The concern is based on animal reproductive toxicity studies that showed adverse developmental effects at high doses. Until human pregnancy safety data exists (and it is not ethical to run randomized trials of drugs in pregnant women), the precautionary principle applies.

Sekhon explains that the current evidence gap creates a real clinical challenge. Women who have finally achieved their best metabolic health on a GLP-1 medication face a decision: stop the drug to try to conceive and risk metabolic regression, or continue the drug and expose a potential pregnancy to an unstudied medication. There is no perfect answer. The best approach is planned discontinuation with a transition plan that includes dietary and exercise strategies to maintain metabolic gains during the washout and conception period.

Oral Contraceptive Interactions

A practical concern that Sekhon raises: GLP-1 medications slow gastric emptying, which is part of how they reduce appetite. Slower gastric emptying can affect the absorption of oral medications, including oral contraceptive pills. If the pill is sitting in a slower-moving stomach, its absorption kinetics may change.

The clinical significance of this interaction is still being studied. Current guidance from manufacturers and reproductive endocrinologists is that women on GLP-1 medications who use oral contraceptives should consider additional or alternative contraception methods, especially during the dose escalation phase when gastric emptying changes are most pronounced. Non-oral options like IUDs, implants, or injections are not affected by gastric motility changes.

This is not a theoretical concern. There are documented cases of oral contraceptive failure in women on GLP-1 medications, though it is difficult to determine the exact failure rate because the interaction has not been studied in a controlled setting. Sekhon's advice is practical: if preventing pregnancy is important to you, use a method that does not depend on gastrointestinal absorption.

PCOS, Weight Loss, and Reproductive Outcomes

Sekhon spends significant time on PCOS because it sits at the intersection of metabolic and reproductive health in a way that makes GLP-1 medications particularly relevant. Women with PCOS have higher rates of insulin resistance, obesity, anovulation (not ovulating), and infertility. They also have higher rates of pregnancy complications including gestational diabetes, preeclampsia, and miscarriage.

Weight loss of even 5 to 10 percent can significantly improve ovulation rates in women with PCOS. GLP-1 medications consistently produce weight loss well above that threshold, which explains why so many women with PCOS are seeing fertility improvements on these drugs. The insulin-sensitizing effects add to the benefit, since insulin resistance is the metabolic driver of the hormonal imbalance in PCOS.

For women with PCOS who are planning pregnancy, Sekhon suggests a strategic approach. Use a GLP-1 medication to achieve weight loss and metabolic improvement. Monitor ovulation through cycle tracking or ultrasound. Once metabolic targets are reached and ovulation is confirmed, discontinue the GLP-1 medication with the appropriate washout period and attempt conception while the metabolic improvements are still in effect. This approach maximizes the fertility benefit of the medication while avoiding exposure during pregnancy.

Male Fertility Considerations

Sekhon briefly addresses male fertility, noting that GLP-1 medications are being used by men as well and the effects on sperm quality and male reproductive hormones are not well studied. Obesity impairs male fertility through lower testosterone, impaired sperm quality, and hormonal disruption. Weight loss generally improves these parameters. Whether GLP-1 medications have any direct effects on testicular function or spermatogenesis beyond what weight loss provides is unknown.

For couples where the male partner is on a GLP-1 medication, Sekhon does not raise the same safety concerns as for female partners, since the drug is not being passed to a developing embryo. But she recommends that men planning to conceive get a semen analysis to establish a baseline, which is good practice regardless of medication status.

Bottom Line for Women on GLP-1 Medications

If you are a woman of reproductive age on a GLP-1 medication, three things matter most. First, use reliable contraception, preferably non-oral methods, if you are not trying to conceive. Second, if you are planning pregnancy, discuss a discontinuation and transition plan with your prescriber well in advance. Third, get thorough hormone and metabolic testing to understand your baseline and track changes. The intersection of GLP-1 treatment and reproductive health is too important to navigate without a clear plan.

Timeline Planning for Women Considering Pregnancy

Sekhon provides a practical timeline that women on GLP-1 medications can use for pregnancy planning. She recommends starting the conversation with your prescriber at least four to six months before you want to start trying to conceive. This gives time for a gradual dose reduction, complete medication washout (minimum two months for semaglutide), and a transition period where you can verify that your metabolic improvements are holding with lifestyle interventions alone.

During the washout period, she recommends increased vigilance about nutrition, exercise, and sleep, the three pillars that help maintain metabolic gains without pharmacological support. Protein intake should remain high. Resistance training should continue. And blood sugar monitoring (even for non-diabetic women) can provide early warning if insulin resistance is returning.

For women who become pregnant unexpectedly while on a GLP-1 medication, Sekhon advises stopping the medication immediately and contacting your prescriber and OB-GYN. While the risk to the pregnancy is theoretical based on animal data rather than confirmed in humans, the precautionary approach is to discontinue as soon as pregnancy is known. The critical period for fetal development is in the first trimester, making early detection of pregnancy important for women on GLP-1 medications who are sexually active and not using reliable contraception.

The Breastfeeding Question

Sekhon addresses another gap in the data that new mothers ask about: can you resume GLP-1 medications while breastfeeding? The current recommendation is no. There is insufficient data on whether semaglutide or tirzepatide is excreted in breast milk and what effects it might have on a nursing infant. Given the lack of data, the precautionary approach is to delay resuming GLP-1 treatment until breastfeeding is complete. For women who want to manage their post-partum weight, she recommends focusing on nutrition, movement, and sleep optimization during the breastfeeding period, with GLP-1 medication as an option once breastfeeding ends. The good news is that breastfeeding itself supports post-partum weight loss for many women, burning roughly 300 to 500 additional calories per day.